Biocracked
←

#arterial stiffness

1 article
A bright, minimalist editorial still life on a pale warm-white stone surface, shot from a slightly elevated three-quarter angle in soft natural window light. At center, a small amber glass supplement bottle with a matte cream label, unbranded, sits beside a few loose white capsules. A pair of weathered hands in a light oatmeal linen sleeve, belonging to an older adult, rests gently near the bottle, with a ceramic mug of tea just out of focus. To the right, a clean glass vial and a delicate glass beaker filled with clear liquid catch the light, hinting at laboratory research without any futuristic touch. A small paper notebook with a handwritten simple line graph rising in a gentle curve lies open nearby, along with a sharpened pencil. Scattered at the edges are soft sprigs of dried eucalyptus and a few pale sage-green leaves, adding an organic note. A faint, abstract molecular diagram printed in muted teal ink on a card leans against the bottle, subtle and graphic. The palette is calm and modern: warm ivory, sage green, soft teal, muted amber, and touches of dusty peach. Long, gentle shadows fall across the surface, and the shallow depth of field blurs the background into creamy neutral tones. The composition leaves generous negative space on the left third for headline text. The overall feel is a trendy health and science journal: clean, airy, trustworthy, and quietly sophisticated, with fine film-like grain and true-to-life color. Ultra-detailed, 16:9 landscape.
supplements

1.000 mg nikotinamid‑ribozida dnevno podiglo NAD+ u krvnim ćelijama za oko 60 % kod starijih odraslih osoba, prema randomizovanom istraživanju

BY DR. SYNAPSE ·

Randomizovano, dvostruko zatvoreno, placebo‑kontrolisano krstajuće ispitivanje u *Nature Communications* iz 2018. godine proučavalo je 500 mg nikotinamid‑ribozida dva puta dnevno (ukupno 1.000 mg) tokom šest nedelja kod zdravih sredovečnih i starijih odraslih osoba. Suplement je bio dobro podnet i podigao nivo NAD+ u imunološkim ćelijama krvi za otprilike 60 % u odnosu na placebo. Istraživači su takođe zabeležili prve naznake mogućeg snižavanja krvnog pritiska i smanjenja arterijske krutosti, ali to su samo podsticaji za veće studije, a ne dokazane koristi. Ovaj članak objašnjava zašto se smatra da NAD+ opada s godinama, šta je studija radila i šta ona ne može da nam kaže o kliničkim ishodima ili dugovečnosti.

This page is available in